These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 24987872)

  • 1. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
    Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
    Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
    Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
    Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.
    Arancibia-Cárcamo CV; Osawa H; Arnett HA; Háskova Z; George AJ; Ono SJ; Ting JP; Streilein JW
    Eur J Immunol; 2004 Feb; 34(2):471-80. PubMed ID: 14768052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
    Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP
    J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
    Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
    Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
    Broxmeyer HE; Cooper S; Hangoc G; Chang CH
    Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed allograft rejection by the suppression of class II transactivator.
    Kim TW; Choi YM; Seo JN; Kim JH; Suh YH; Chung DH; Jung KC; Oh KI
    Exp Mol Med; 2006 Jun; 38(3):210-6. PubMed ID: 16819279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
    Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein.
    Wang Y; Xu M; Che M; Von Hofe E; Abbas A; Kallinteris NL; Lu X; Liss ZJ; Forman JD; Hillman GG
    Hum Gene Ther; 2005 Feb; 16(2):187-99. PubMed ID: 15761259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
    Meissner M; Whiteside TL; Kaufmann R; Seliger B
    Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New strategies of mammary cancer vaccination.
    Accolla RS; Frangione V; De Lerma Barbaro A; Mortara L
    Breast J; 2010; 16 Suppl 1():S42-4. PubMed ID: 21050309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide inhibits INFgamma-induced increases in CIITA mRNA abundance and activation of CIITA dependent genes--class II MHC, Ii and H-2M. Class II TransActivator.
    Kielar ML; Sicher SC; Penfield JG; Jeyarajah DR; Lu CY
    Inflammation; 2000 Oct; 24(5):431-45. PubMed ID: 10921507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Major histocompatibility complex class II transactivator (CIITA) hammer- head ribozyme transfer inhibits major histocompatibility complex class II (MHC-II) expression in Jukart cells].
    Guo R; Zou P; Song YP; Ma J; Lu HZ; Cao YL; Tong YJ
    Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):925-8. PubMed ID: 14723817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
    Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
    Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
    Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
    Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection.
    Felix NJ; de Serres S; Meyer AA; Ting JP
    J Surg Res; 2002 Feb; 102(2):185-92. PubMed ID: 11796017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.